E63: Insurrection indictments, human rights in the US and abroad, groundbreaking MS study

conviction thresholds crossed by this episode — 65 / 45 / 15 · ideas born here show where they landed. why 65 isn't always green

each voice's force on conviction this episode — supports and opposes, weighted exactly as the replay applied them · share = % of this episode's movement

Friedberg

2 captures · 57% of movement · 1 idea born

+36.2 → net +36.2

Chamath

3 captures · 39% of movement

+14.6 / -10.1 → net +4.5

Jason

1 capture · 4% of movement

+0.0 / -2.7 → net -2.7

written during extraction and stored in data/extractions/ep063.json — the auditable source of truth, including everything market-adjacent that did not earn a capture

A genuinely thin episode for tradeable content - roughly 60 of 85 minutes is a three-way moral argument with no instrument attached to it, and Sacks ends the episode with zero captures. Act one is round three of the January 6th fight: Sacks calls it media-manufactured threat inflation, warns the surveillance/prosecutorial expansion is the real risk, and table-pounds a November 'red wave... landslide' three separate times (1:32, 3:34, 5:58) - a dated, repeated, high-conviction political prediction that is deliberately NOT captured because he draws no market conclusion from it and there is no honest US-listed instrument for a midterm outcome. Sacks' constructive ask is Electoral Count Act reform plus a congressional insider-trading ban (Chamath agrees twice); both are policy chatter with no play. Act two is the notorious Uyghur segment - Chamath's 'nobody cares about what's happening to the Uyghurs... it is below my line' and 'luxury belief' framing, Jason's Amnesty-International idealism, Friedberg's Dalio-flavoured narrative relativism (US incarcerates 2.3M of 340M vs China 1.7M of 1.4B), Sacks defending MBS on the Abraham/Doha normalisation track. Three real market-relevant things fall out of it, all Chamath and Friedberg: Chamath discloses he is 'spending a lot of time and money actually trying to fortify America's supply chain... from a practical capitalist perspective' (20:29) - the first-person money version of the reshoring thesis, captured as positioning on supply-chain-resilience-reshoring-2021; Chamath restates his standing Taiwan call in passing - 'our economy could turn on a dime if China invades Taiwan' (15:30), a strength-1 reinforcement of china-taiwan-silicon-chokepoint-2021; and Friedberg makes the episode's one macro forecast, that the US and China are at the turn of a multi-hundred-year cycle and 'I don't think we're going to hear a lot of good news about China for the next decade from any politician in the United States' (22:43), taken as a new bearish-China politics-market idea at a stated 10-year horizon. Explicitly rejected from this segment: Jason's 'there will be increased pressure on all companies that are engaging in China over human rights' (a restatement of the just-signed Uyghur Forced Labor Prevention Act, with Chamath's sarcastic 'So Apple and Tesla?' as the only instruments named by anyone) and his normative case for capital allocators disengaging from Saudi/Chinese money - advocacy, not prediction. Also rejected: Chamath's 'cognitive impairment of our children' human-rights framing (no instrument), and Sacks' callback that 'the rise of authoritarianism... was one of my big trends in the prediction episodes' (57:36), which is applied domestically to US censorship and surveillance with no market claim and therefore is NOT attached to E61's global-conflict-energy-defense. Act three is the actual alpha: Friedberg's science corner on the Science paper (published the previous day) using 62M frozen US-military blood samples across 10M service members 1993-2013 to show that of ~800 EBV-negative people who later developed MS, 100% seroconverted first, versus ~50% of controls - a 32x risk ratio with 20 other viruses excluded. He draws the commercial conclusion explicitly: EBV was never worth chasing because 'who the hell cares about mono', but if it causes MS ($40k/yr/patient, $30B/yr US spend) then 'there's a reason to go after it, a lot of money to go after it', naming T-cell therapy (a company Chamath sent round on group text, unnamed on air), mRNA (Jason: 'aren't we doing an mRNA vaccine for Epstein-Barr?' - yes), Takeda's antiviral maribavir, and a repurposed antihypertensive steroid, and closing that 'this paper... is really going to catalyze investment.' Chamath is the bear on it, and notably on economics rather than science: two-thirds of adults under 55 carry the virus, so you are talking about inoculating the world, and 'there's a cost issue, there's a manufacturability issue, and then there's an ROI issue that unfortunately will be adjudicated.' That two-sided exchange is the new ebv-causes-ms-therapeutic-target-2022 idea. The pig-heart xenotransplant (David Bennett, Jan 7, Baltimore) follows: Chamath's reaction is personal and non-directional ('my father was on a kidney transplant registry for eight years'), and only Friedberg's closing 'now that we have gene editing and potentially have the ability to grow biological matter in bioreactors, it's going to be tremendous' is captured, as a strength-1 support on gene-editing-platform-validated-2021. Jason's one throwaway macro line - 'thank God, it feels like Omicron is leading us out of this' (1:02:11) - is captured as a strength-1 oppose on covid-variant-wave-tough-winter-2021. Disclosed positions and personal money: Chamath is funding US supply-chain fortification, took money from an unnamed Chinese billionaire early on (with a morality clause barring gambling/alcohol/cannabis), refused an LP convicted of domestic abuse, and says he takes no Saudi money ('it's my own capital'); Jason has invested in wagering apps and is 'thinking about creating a syndicate specifically for gambling and wagering', and has LPs in his active fund who exclude wagering. On the E61 annual predictions: only two of the six surface at all and neither generates a mention - nothing on battery metals, crypto shakeout, QE end, US boom or Visa/Mastercard. What does get re-litigated is a Jason E61 prediction that was never captured as a tradeable idea: Chamath teases him at 1:17:00 that a Democratic SEC commissioner wants to make accredited-investor rules *stricter*, i.e. the opposite of Jason's call - 'that was your big prediction' - and Jason burns two minutes advocating a test-based accreditation regime with a 5-10% of income cap. No reversals by any original proposer anywhere in the episode. Label anomalies: none - see the receipts note; labels are clean. Friedberg's 38 turns is low but genuine, he sits out the first 20 minutes on purpose ('I have nothing to say today. I'm just going to sit here and watch. I brought popcorn.') and then does the two longest monologues in the episode. Episode ends 1:24:55 with Sacks reading his Comedy Central-written Phil Hellmuth roast material - pure bit, no content.